6 Colo. Code Regs. § 1009-7-A

Current through Register Vol. 47, No. 11, June 10, 2024
Appendix 6 CCR 1009-7-A - Reportable Environmental and Chronic Diseases

Disease/Event

Type

Time

Reporter

Adverse drug reaction or overdose caused by taking a prescription drug, over-the-counter medication or remedy, controlled substance (legally or illegally obtained) that results in treatment in an emergency department, hospitalization, or death

120 days1

P*

Autism Spectrum Disorders (ASD) (Age less than or equal to ten years) (Including Autistic Disorder, Asperger's Syndrome, and Pervasive Developmental Disorder-Not Otherwise Specified)

30 days

P**

Chromosomal abnormalities and neural tube defects diagnosed by prenatal testing or by genetic testing in Colorado residents through the third birthday

90 days

P

Fetal Alcohol Syndrome (Age &<= 10 years)

30 days

P

Head injuries requiring admission to hospitals or resulting in death

120 days1

L & P*

Lead Level, elevated

Blood lead level &>= 5 µg/dL AND age &<= 18 years

7 days

L & P***

Blood lead level &>= 5 µg/dL if age &>18 years

30 days

L & P***

Blood lead level <5 µg/dL AND age &<= 18 years

30 days

L & P***

Mercury Level, elevated

Blood mercury >0.5 µg/dL

30 days

L

Urine mercury >20 µg/L

30 days

L

Muscular Dystrophies

120 days1

P

Spinal Cord Injuries

120 days1

L & P*

Birth defects, developmental disabilities, and medical risk factors for developmental delay in Colorado residents diagnosed prenatally, at birth, or through the third birthday; with the exception of muscular dystrophies, which shall be reported without age limit2

Major congenital malformations, deformations and chromosomal abnormalities

120 days1

L & P*

Congenital (perinatal) infections, including:

Congenital syphilis Congenital rubella Cytomegalovirus Toxoplasmosis/herpes viral/herpes simplex Neonatal viral hepatitis

120 days1

L & P*

Sensory impairments, including:

Hearing loss Blindness and low vision

120 days1

L & P*

Other disabilities, including:

Specific delays in development Change to Intellectual Disability Infantile cerebral palsy Autism spectrum disorders (ASD)

120 days1

L & P*

Newborn

genetic/endocrine/metabolic and newborn immunodeficiencies diseases

120 days1

L & P*

Infections, including:

Encephalitis Meningitis

120 days1

L & P*

Injuries, including:

Traumatic brain injuries Spinal cord injuries

120 days1

L & P*

Other disabilities and medical conditions related to development, including:

Convulsions/seizures

Specific delays in development

Intellectual disabilities

Infantile cerebral palsy

Autism spectrum disorders

(ASD)

Drug withdrawal syndrome in

120 days1

L & P*

the newborn

Failure to thrive

Infantile spasms

Muscular dystrophies

Noxious influences affecting fetus (includes Fetal Alcohol

Syndrome)

Werdnig Hoffman disease

Amniotic bands

Perinatal Intracranial hemorrhage

Slow fetal growth and fetal malnutrition

1 Reporting time is 120 days unless it is to be reported sooner under a different statutory or regulatory authority.

2 Listed conditions relate directly to the International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM)

Reporter: The party responsible for reporting is indicated by one of the following:

L = Laboratory (whether or not associated with a hospital; by out-of-state laboratories that maintain an office or collection facility in Colorado; and by in-state laboratories which send specimens to an out-of-state laboratory referral laboratory).

P = Health care providers, coroners, laboratories, hospitals.

* Reporting requirement is fulfilled through Department access to administrative data sets including but not limited to hospitalization and emergency discharge data and vital records data, unless notified by the Department that additional data are necessary or otherwise required by statute or regulation.

** Condition reportable only among residents of seven-county Denver Metropolitan Area

(Adams, Arapahoe, Boulder, Broomfield, Denver, Douglas and Jefferson Counties).

*** Laboratory as specified above or by the physician, healthcare provider, or clinic when blood lead specimens are analyzed in an office or outpatient setting (i.e., using LeadCare® II instrument).

6 CCR 1009-7-A

40 CR 24, December 25, 2017, effective 1/14/2018